###begin article-title 0
SIRT1 genetic variants associate with the metabolic response of Caucasians to a controlled lifestyle intervention - the TULIP Study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 320 326 320 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 150 156 <span type="species:ncbi:9606">humans</span>
###xml 266 271 <span type="species:ncbi:9606">human</span>
Sirtuin1 (SIRT1) regulates gene expression in distinct metabolic pathways and mediates beneficial effects of caloric restriction in animal models. In humans, SIRT1 genetic variants associate with fasting energy expenditure. To investigate the relevance of SIRT1 for human metabolism and caloric restriction, we analyzed SIRT1 genetic variants in respect to the outcome of a controlled lifestyle intervention in Caucasians at risk for type 2 diabetes.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 111 117 111 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 565 571 565 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
A total of 1013 non-diabetic Caucasians from the Tuebingen Family Study (TUEF) were genotyped for four tagging SIRT1 SNPs (rs730821, rs12413112, rs7069102, rs2273773) for cross-sectional association analyses with prediabetic traits. SNPs that associated with basal energy expenditure in the TUEF cohort were additionally analyzed in 196 individuals who underwent a controlled lifestyle intervention (Tuebingen Lifestyle Intervention Program; TULIP). Multivariate regressions analyses with adjustment for relevant covariates were performed to detect associations of SIRT1 variants with the changes in anthropometrics, weight, body fat or metabolic characteristics (blood glucose, insulin sensitivity, insulin secretion and liver fat, measured by magnetic resonance techniques) after the 9-month follow-up test in the TULIP study.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 100 102 100 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 149 151 149 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 292 294 292 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 367 369 367 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 441 443 441 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Minor allele (X/A) carriers of rs12413112 (G/A) had a significantly lower basal energy expenditure (p = 0.04) and an increased respiratory quotient (p = 0.02). This group (rs12413112: X/A) was resistant against lifestyle-induced improvement of fasting plasma glucose (GG: -2.01%, X/A: 0.53%; p = 0.04), had less increase in insulin sensitivity (GG: 17.3%, X/A: 9.6%; p = 0.05) and an attenuated decline in liver fat (GG: -38.4%, X/A: -7.5%; p = 0.01).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 192 198 192 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
SIRT1 plays a role for the individual lifestyle intervention response, possibly owing to decreased basal energy expenditure and a lower lipid-oxidation rate in rs12413112 X/A allele carriers. SIRT1 genetic variants may, therefore, represent a relevant determinant for the response rate of individuals undergoing caloric restriction and increased physical activity.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 82 83 82 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
The sirtuin SIRT1 (silent mating type information regulation 2 homolog 1) is a NAD+-dependent deacetylase involved in regulation of glucose metabolism in different organs [1,2]. SIRT1 directs its deacetylase activity against histones, a process that facilitates the formation of heterochromatin with subsequent repression of gene transcription. In addition, SIRT1 directly regulates activity of metabolic transcription factors and their co-activators, as e. g. forkhead transcription factor FOXO1, nuclear factor NF-kappaB (nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) or PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1 alpha).
###end p 11
###begin p 12
###xml 257 258 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 391 392 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 536 537 525 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 805 806 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 823 824 812 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 965 966 954 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 568 572 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 740 744 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 887 891 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Due to its ubiquitous expression, SIRT1 activity is relevant for many insulin-sensitive organs. In adipose tissue, SIRT1 down-regulates fat storage by increased lipolysis via the inactivation of PPARgamma (peroxisome proliferator-activated receptor gamma) [3]. In pancreatic beta-cells, SIRT1 enhances glucose-stimulated insulin secretion via down-regulation of UCP2 (uncoupling protein 2) [4]. In the liver, particularly under low-nutrient conditions, SIRT1 induces gluconeogenesis and inhibits glycolysis by deacetylating PGC-1alpha [5]. In skeletal muscle of obese mice, SIRT1 mediates the insulin sensitizing effect of resveratrol. The antioxidant resveratrol induces increased exercise endurance and higher basal energy expenditure in mice, thereby promoting resistance against diet-induced obesity [6] and mortality [7]. Interestingly, modest overexpression of SIRT1 also protects mice against high-fat diet induced glucose intolerance and hepatic steatosis [8], so that SIRT1 may represent a promising future pharmacological target to prevent the metabolic sequelae of chronic exposure to a high-fat diet.
###end p 12
###begin p 13
###xml 180 186 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 433 439 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 515 516 515 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 577 583 577 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 821 827 821 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 1101 1102 1101 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 136 142 <span type="species:ncbi:9606">humans</span>
###xml 505 513 <span type="species:ncbi:9606">patients</span>
Summarizing all these data, one may assume that human SIRT1 genetic variants may also play a role in lifestyle intervention response in humans. So far, no studies exist on whether SIRT1 genetic variants affect the individual metabolic susceptibility to caloric restriction or increased physical activity. The only genetic study that assessed SIRT1 genetic variants in the context of metabolism and diabetes reports an association of SIRT1 genetics with basal energy expenditure in Finnish type 2 diabetic patients [6]. We, therefore, conducted the present study to investigate SIRT1 variants in the context of a controlled lifestyle intervention in prediabetic individuals at high risk for later onset of diabetes. For this purpose, 1013 subjects from the cross-sectional Tuebingen Family Study (TUEF) were genotyped for SIRT1 tagging SNPs and association analyses for energy expenditure and other metabolic traits were undertaken. In a second step, genotypes that associated with different phenotypes in the TUEF cohort were analyzed in the ongoing Tubingen Lifestyle Intervention Programme (TULIP) [9] for longitudinal changes of blood glucose, insulin secretion, insulin sensitivity and liver fat.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 17 29 <span type="species:ncbi:9606">participants</span>
Study design and participants
###end title 15
###begin p 16
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 591 592 591 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 982 983 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 153 165 <span type="species:ncbi:9606">participants</span>
###xml 303 315 <span type="species:ncbi:9606">participants</span>
###xml 470 482 <span type="species:ncbi:9606">participants</span>
All volunteers signed written consent to the study protocol, approved by the local medical ethics committee. Genotyping for SIRT1 was done in 1013 study participants, 96 of which were excluded (manifest diabetes or missing data), resulting in a total cohort of n = 917 for cross-sectional analyses. 196 participants of the study cohort also participated in TULIP, so that longitudinal (9 month) data on metabolic traits including liver fat content were available. TULIP participants are at increased risk of type 2 diabetes (family history of type 2 diabetes, body mass index (BMI) > 27 kg/m2, diagnosis of IGT or previous diagnosis of gestational diabetes) and undergo a controlled lifestyle intervention designed for the same targets as the Diabetes Prevention Study [10]: body weight reduction by > 5%, dietary fat (saturated fatty acids) reduction to < 30% (< 10%) of caloric intake, increase of dietary fibre (> 15 g/1000 kcal) and enhanced physical activity (> 3 h/week; see [9] for further details on TULIP).
###end p 16
###begin title 17
Oral glucose tolerance test (OGTT)
###end title 17
###begin p 18
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 4 16 <span type="species:ncbi:9606">participants</span>
All participants underwent an OGTT performed according to WHO recommendations [11]. Blood glucose, plasma insulin, plasma C-peptide and non-esterified fatty acid (NEFA) levels were determined at 0, 30, 60, 90 and 120 min intervals.
###end p 18
###begin title 19
Insulin sensitivity, insulin secretion, and analytical methods
###end title 19
###begin p 20
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 711 713 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Blood glucose was determined using a bedside glucose analyzer (Yellow Springs Instruments, Yellow Springs, CO, USA). Plasma insulin was determined by microparticle enzyme immunoassay (Abbott Laboratories, Tokyo, Japan), and plasma C-peptide was determined by radioimmunoassay (Byk-Sangtec, Dietzenbach, Germany). Insulin sensitivity was estimated using the model from Matsuda and DeFronzo [12], and insulin secretion was estimated from 30 min C-peptide levels obtained during the OGTT. Basal energy expenditure and respiratory quotient were measured with a DELTATRACtrade mark Metabolic Monitor (Hoyer; Bremen, Germany) under resting conditions. Further details on analytical procedures are provided elsewhere [13].
###end p 20
###begin title 21
Determination of body and liver fat
###end title 21
###begin p 22
###xml 229 232 229 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 413 414 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
Total body fat and lean body mass were measured by bioelectrical impedance (RJL; Detroit, MI, USA). Liver fat was determined by magnetic resonance spectroscopy (1.5T Magnetom Sonata; Siemens, Erlangen, Germany) in the posterior 7th segment of the liver. A single-voxel stimulated echo acquisition mode technique was applied (repetition time = 4 s, echo time = 10 msec, 32 acquisitions) for a voxel of 3 x 3 x 2 cm3, and liver fat content was calculated by the signal integral (methylene/methyl signals between 0.7-1.5 ppm) in reference to the sum of water and lipid signal integrals [14].
###end p 22
###begin title 23
Genotyping
###end title 23
###begin p 24
###xml 311 312 311 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
The TaqMan assay (Eurogentec; Liege, Belgium) and the fluorescence detecting ABI Prism 7500 (Applied Biosystems; Foster City, CA, USA) were used for genotyping of SNPs selected by HapMap analysis (phase I, release 21a, January 2007). A minor allele frequency (MAF) > 0.05 and a linkage disequilibrium measure (r2) < 0.8 were prerequisites for tagging SNP selection in a region comprising the whole SIRT1 gene and 10 kb of its promoter. To monitor TaqMan test reproducibility and accuracy, samples of 50 individuals were sequenced for the selected tagging SNPs with an ABI Prism 310 genetic analyser (Applied Biosystems). Subsequently, one sample per allelic combination was included in each TaqMan assay as a known reference genotype control.
###end p 24
###begin title 25
Statistics
###end title 25
###begin p 26
###xml 92 93 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 371 373 367 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Data are presented as means +/- SD. The Hardy-Weinberg equilibrium was calculated by the chi2-test. Multivariate linear regression analyses with adjustments for relevant covariates were undertaken, using logarithmically transformed data for non-normally distributed parameters. The JMP 4.0.4 software (SAS Institute; Cary, NC, USA) was used for statistical analyses, and p values </= 0.05 were considered statistically significant.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
SIRT1 genetic variants in the TUEF/TULIP cohort
###end title 28
###begin p 29
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 379 381 379 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 452 453 452 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Four SNPS of the SIRT1 gene (~35 kb, 9 exons) on chromosome 10q21.3 were selected from the HapMap according the selection criteria for genotyping: rs730821 (A/G, MAF = 0.186 in the TUEF cohort, promoter), rs12413112 (G/A, MAF = 0.114, intron4), rs7069102 (G/C, MAF = 0.301, intron4) and rs2273773 (T/C, MAF = 0.058, intron5). All tagging SNPs were in Hardy-Weinberg-Equilibrium (p > 0.21; all, both TUEF and TULIP cohort), and linkage disequilibrium (r2) ranged from 0.008 to 0.53.
###end p 29
###begin title 30
Cross-sectional TUEF study
###end title 30
###begin p 31
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 226 228 226 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 267 269 267 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 575 577 575 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 611 612 611 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 888 890 888 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 912 913 912 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1023 1029 1023 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
We first verified whether SIRT1 genetic variants associate with basal energy expenditure in the TUEF cohort, as shown before in a Finnish population [6]. Indeed, basal energy expenditure was significantly lower in rs12413112 (p = 0.04; dominant model) and rs7069102 (p = 0.05; dominant model) minor allele carriers compared to homozygous carriers of the major G alleles, after adjustment for relevant covariates as age, sex, lean body mass and body fat [15-17]. Minor allele carriers of rs12413112, in addition, had a significantly increased respiratory quotient (RQ; +2.2%, p = 0.02; dominant model; see Table 1). In contrast, anthropometrics (BMI, body fat, waist-to-hip ratio) did not differ among SIRT1 genotypes. There was no significant association with (fasting and 2 h OGTT) glucose and insulin plasma levels, insulin sensitivity (OGTT and clamped) or insulin secretion (dominant p for all > 0.12; Table 1). Serum lipid parameters (total-, HDL-, LDL-cholesterol, apolipoproteins, NEFAs) did also not differ between SIRT1 genotypes (data not shown).
###end p 31
###begin p 32
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1</italic>
Distribution of anthropometrics and metabolic traits in the TUEF cohort according to rs12413112, rs7069102, rs730821 and rs2273773 in SIRT1
###end p 32
###begin p 33
Data are presented as means +/- SD; AU, arbitrary units
###end p 33
###begin p 34
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 17 19 15 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 25 26 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 112 113 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 252 253 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 253 255 251 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 261 273 <span type="species:ncbi:9606">participants</span>
aAccording to chi2 test; bWaist-to-hip ratio, body mass index (BMI) and body fat were adjusted for age and sex; cAll the following parameters were adjusted for age, sex and body fat; insulin secretion was additionally adjusted for insulin sensitivity; dn = 375 participants; basal energy expenditure was adjusted to age, sex, lean body mass and body fat.
###end p 34
###begin title 35
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
SIRT1 variants and TULIP lifestyle intervention outcome traits
###end title 35
###begin p 36
###xml 8 14 8 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
The two SIRT1 SNPs that associated with energy expenditure, namely rs12413112 and rs7069102, were subsequently analyzed in 196 individuals (118 females, 78 males, aged 45.8 +/- 11.2 years; GG: n = 151, GA: n = 42, AA: n = 3 individuals) from the TULIP study cohort who had completed the 9-month follow-up test. In this cohort, average weight loss amounted to 2.56 +/- 4.06 kg in a follow-up time of 259 +/- 53 days, resulting in a BMI reduction of 0.87 +/- 1.38.
###end p 36
###begin p 37
###xml 83 85 83 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 101 103 101 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 272 274 272 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 469 471 469 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 676 678 676 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
We did not detect significant associations between rs12413112 genotype and weight (p = 0.37) or BMI (p = 0.38) change. By contrast, minor allele carriers of rs12413112 were resistant against lifestyle-induced improvement of fasting plasma glucose (GG: -2.01%, X/A: 0.53%; p = 0.04, adjusted for age, sex, follow-up time, BMI at baseline and follow-up and fasting plasma glucose at baseline; Fig. 1A), had a weaker increase in insulin sensitivity (GG: 17.3%, X/A: 9.6%; p = 0.05, adjusted for age, sex, follow-up time, BMI at baseline and follow-up and insulin sensitivity at baseline; Fig. 1B) and a remarkably attenuated decline in liver fat content (GG: -38.4%, X/A: -7.5%; p = 0.01, adjusted for age, sex, follow-up time, BMI at baseline and follow-up and liver fat content at baseline; Fig. 1C). The effect on liver fat content remained significant even after Bonferroni's correction for multiple testing (2 tests: energy expenditure and obesity), and we had a power of 0.76 to detect this effect. The rs12413112 genotype effects on fasting glucose (0.50) and insulin sensitivity (0.56) change did not show a sufficient statistical power and also did not remain significant after correction for multiple comparisons. The rs7069102 genotype did not significantly associate with longitudinal changes in weight (p = 0.40; dominant model), BMI (p = 0.41), fasting glucose (p = 0.08), insulin sensitivity (p = 0.45) and liver fat (p = 0.09) in the longitudinal TULIP analysis.
###end p 37
###begin p 38
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 0 120 0 120 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Interaction of rs12413112 <italic>SIRT1 </italic>genotype with the metabolic responses during a controlled 9-month lifestyle intervention</bold>
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 736 748 <span type="species:ncbi:9606">participants</span>
Interaction of rs12413112 SIRT1 genotype with the metabolic responses during a controlled 9-month lifestyle intervention. Rs12413112 SIRT1 genotype (GG): filled circles (‚óè); X/A: opened circles (o). a) Response of plasma glucose determined during the fasting state. b) Response of insulin sensitivity estimated by the formula from Matsuda et al. [12]. c) Response of liver fat content, determined by magnetic resonance spectroscopy. For statistical analyses, all data were log-transformed and adjusted for age, sex, follow-up-time, BMI at both baseline and follow-up and the corresponding variable (plasma glucose, insulin sensitivity or liver fat) measured at baseline. Data are presented as means+SEM (G/G: n = 152, X/A: n = 45 TULIP participants).
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 315 321 315 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 751 757 751 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 763 764 763 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1229 1235 1229 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
This is the first study to have analysed the impact of SIRT1 genetic variants on the outcome of a lifestyle intervention in a diabetes risk population. Despite numerous works demonstrating SIRT1 function in different insulin-responsive tissues [1,3-5,18,19], we were not able to verify a significant association of SIRT1 variants with plasma glucose, plasma insulin, NEFAs, serum lipids, insulin sensitivity or insulin secretion, both under fasting conditions and 2 h OGTT in the cross-sectional analyses. However, minor allele carriers of rs12413112 had significantly lower basal energy expenditure and an increased respiratory quotient (RQ) at baseline. Interestingly, in a Finnish population, higher basal energy expenditure was reported for three SIRT1 SNPs [6]. This difference may be due to the very low linkage disequilibrium of these three SNPs with rs12413112, ranging from 0.0076 to 0.10 in both the TUEF cohort as well as the CEU population of the HapMap project, so that rs12413112 may act in the opposing direction on SIRT1 function compared to the previously reported SNPs. In addition, our study cohort has considerably differing allele frequencies compared to the investigated Finnish population, at least in the SIRT1 locus.
###end p 40
###begin p 41
###xml 560 561 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 643 649 643 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 782 788 782 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 554 558 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
The minor allele of rs12413112 is associated with unresponsiveness of fasting plasma glucose, insulin sensitivity and liver fat to a controlled 9 month lifestyle intervention. Because of the higher RQ in this subgroup, one may speculate that the rs12413112 minor A-allele contributes to a lower rate of lipid-oxidation, resulting in the observed lower liver fat reduction, despite dietary changes and increased physical activity. Taking into account that modest overexpression of SIRT1 leads to protection from high-fat diet induced hepatic steatosis in mice [8], our study let assume that the minor allele of rs12413112 may negatively affect SIRT1 expression, especially as the SNPs tagged by this intronic SNP, namely rs11599151, rs11599524 and rs12778366, are all located in the SIRT1 promoter.
###end p 41
###begin p 42
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
Finally, the rather small study sample size has to be mentioned as the major statistical limitation of this study. The here reported effects of SIRT1 variants are statistically significant, but a conservative adjustment for multiple comparisons would render the associations in TUEF with energy expenditure and RQ non-significant. However, we think that our findings are relevant, as the TULIP study provides a very precisely phenotyped and closely monitored lifestyle intervention cohort which is suitable for studying the role of genetic variants by a classical candidate-gene approach.
###end p 42
###begin title 43
Conclusion
###end title 43
###begin p 44
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 206 212 206 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 259 265 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 356 364 356 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AdipoR1 </italic>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 373 383 373 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR&#948; </italic>
###xml 384 386 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 389 395 385 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
###xml 585 591 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SIRT1 </italic>
In summary, our study shows that SIRT1 genetic variants may affect individual susceptibility to caloric restriction and increased physical activity. Although the cross-sectional study let rather doubt that SIRT1 does represent a classical diabetes risk gene, SIRT1 genetic variants may determine the individual response to a lifestyle intervention. Beyond AdipoR1 [14] and PPARdelta [20], SIRT1 is the third gene detected which does not affect prediabetic traits in a cross-sectional study approach, but which remarkably influences the response to a lifestyle intervention. Therefore, SIRT1 should be elucidated in other prospective lifestyle intervention studies, and further research on SIRT1 as a potential pharmacological target for prevention of type 2 diabetes is warranted.
###end p 44
###begin title 45
Competing interests
###end title 45
###begin p 46
The authors declare that they have no competing interests.
###end p 46
###begin title 47
Authors' contributions
###end title 47
###begin p 48
###xml 232 244 <span type="species:ncbi:9606">participants</span>
###xml 486 493 <span type="species:ncbi:9606">patient</span>
PW was responsible for the complete statistical analysis and prepared all tables, figures and the manuscript. FM is responsible of the genotyping facility at the University of Tubingen. JR made contributions to phenotyping of TULIP participants. JM and FS performed the magnetic resonance spectroscopy studies for liver fat determination. OT contributed to the statistical analysis. NS, AF and HUH acted as principal investigators for the TUEF and TULIP study, and were responsible for patient and data management. All authors contributed to the preparation of the manuscript.
###end p 48
###begin title 49
Pre-publication history
###end title 49
###begin p 50
The pre-publication history for this paper can be accessed here:
###end p 50
###begin p 51

###end p 51
###begin title 52
Acknowledgements
###end title 52
###begin p 53
###xml 499 511 <span type="species:ncbi:9606">participants</span>
We thank all the research volunteers for their participation. We gratefully acknowledge the technical assistance of Melanie Weisser, Alke Guirguis, Roman-Georg Werner and Anna Bury. Norbert Stefan is currently supported by a Heisenberg Grant of the Deutsche Forschungsgemeinschaft (DFG). The TULIP study is supported by a grant from the DFG (KFO 114 and Heisenberg-Grant to Norbert Stefan 1096/1-1) and the European Community's FP6 EUGENE6 (LSHM-CT-2004-512013). The authors would like to thank all participants for their cooperation.
###end p 53
###begin article-title 54
SIRT1 and endocrine signaling
###end article-title 54
###begin article-title 55
Sirtuin functions in health and disease
###end article-title 55
###begin article-title 56
Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma
###end article-title 56
###begin article-title 57
Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells
###end article-title 57
###begin article-title 58
Nutrient control of glucose homeostasis through a complex of PGC- 1alpha and SIRT1
###end article-title 58
###begin article-title 59
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha
###end article-title 59
###begin article-title 60
###xml 44 48 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Resveratrol improves health and survival of mice on a high-calorie diet
###end article-title 60
###begin article-title 61
Sirt1 protects against high-fat diet-induced metabolic damage
###end article-title 61
###begin article-title 62
Lifestyle intervention in individuals with normal versus impaired glucose tolerance
###end article-title 62
###begin article-title 63
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
###end article-title 63
###begin article-title 64
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
###end article-title 64
###begin article-title 65
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp
###end article-title 65
###begin article-title 66
Role of AMP-activated protein kinase gamma 3 genetic variability in glucose and lipid metabolism in non-diabetic whites
###end article-title 66
###begin article-title 67
Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat
###end article-title 67
###begin article-title 68
###xml 46 49 <span type="species:ncbi:9606">man</span>
Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber
###end article-title 68
###begin article-title 69
Positive association between resting energy expenditure and weight gain in a lean adult population
###end article-title 69
###begin article-title 70
###xml 59 62 <span type="species:ncbi:9606">man</span>
Determinants of energy expenditure and fuel utilization in man: effects of body composition, age, sex, ethnicity and glucose tolerance in 916 subjects
###end article-title 70
###begin article-title 71
The Direct Involvement of SirT1 in Insulin-induced Insulin Receptor Substrate-2 Tyrosine Phosphorylation
###end article-title 71
###begin article-title 72
SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions by Repressing PTP1B
###end article-title 72
###begin article-title 73
Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study
###end article-title 73

